Cargando…
Serotype-Specific Killing of Large Cell Carcinoma Cells by Reovirus
Reovirus is under development as a therapeutic for numerous types of cancer. In contrast to other oncolytic viruses, the safety and efficacy of reovirus have not been improved through genetic manipulation. Here, we tested the oncolytic capacity of recombinant strains (rs) of prototype reovirus labor...
Autores principales: | Simon, Emily J., Howells, Morgan A., Stuart, Johnasha D., Boehme, Karl W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5490817/ https://www.ncbi.nlm.nih.gov/pubmed/28587298 http://dx.doi.org/10.3390/v9060140 |
Ejemplares similares
-
Current understanding of reovirus oncolysis mechanisms
por: Phillips, Matthew B, et al.
Publicado: (2018) -
The oncolytic effect in vivo of reovirus on tumour cells that have survived reovirus cell killing in vitro
por: Alain, T, et al.
Publicado: (2006) -
Preinduced reovirus-specific T-cell immunity enhances the anticancer efficacy of reovirus therapy
por: Groeneveldt, Christianne, et al.
Publicado: (2022) -
Glycan Engagement Dictates Hydrocephalus Induction by Serotype 1 Reovirus
por: Stencel-Baerenwald, Jennifer, et al.
Publicado: (2015) -
The GM2 Glycan Serves as a Functional Coreceptor for Serotype 1 Reovirus
por: Reiss, Kerstin, et al.
Publicado: (2012)